One approach is to target multiple antigens, such as CD19 and CD22, whether from a bispecific “tandem” CAR (e.g., 5) or by sequential administration of CARs with different specificities (e.g., (17, 18)), thereby restricting the avenues of tumor escape. This evidence concerns the gene CD22 and neoplasm.